Christian Rolfo: Bintrafusp Alfa Plus Chemotherapy in Patients With Stage IV NSCLC
Christian Rolfo, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, shared a post on X:
“Our paper is online at Journal of Toracic Oncology.
‘Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.'”
Authors: Christian Rolfo, Laurent Greillier, Remi Veillon, Firas Badin, Francois Ghiringhelli, Nicolas Isambert, Astrid Paulus, Surendra Pal Chaudhary, Yulia Vugmeyster, Masashi Sato, Sandrine Hiret,
More posts Christian Rolfo.
Christian Rolfo MD, PhD, MBA, Dr.hc. is the Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University. He also serves as a Professor of Internal Medicine -Oncology at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute. He has authored over 350 scientific articles & contributions to book chapters.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023